This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KOOL Cesca Therapeutics (KOOL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsDividendOwnershipTrendsBuy This Stock About Cesca Therapeutics Stock (NASDAQ:KOOL) 30 days 90 days 365 days Advanced Chart Get Cesca Therapeutics alerts:Sign Up Key Stats Today's Range$11.72▼$11.7650-Day Range$2.11▼$5.1452-Week Range$2.10▼$7.00Volume13,783 shsAverage Volume112,188 shsMarket Capitalization$28.32 millionP/E RatioN/ADividend Yield0.50%Price TargetN/AConsensus RatingN/A Company OverviewCesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products. It offers AutoXpress System, a proprietary automated device and companion sterile disposable for concentrating hematopoietic stem cells from cord blood; Point-of-CareXpress System, a proprietary automated device and companion sterile disposable for the isolation and concentration of hematopoietic stem cells from bone marrow; CAR-TXpress System, a suite of multi-component automated system that allows the automated manufacturing, expansion, and storage of cellular therapies for immuno-oncology; BioArchive System, an automated cryogenic device for single-cassette based cryo-storage of biological license applications products; and manual bag sets for use in the processing and cryogenic storage of cord blood. The company is also developing autologous stem cell-based therapies that address medical needs for applications in the vascular, cardiology, and orthopedic markets. In addition, it provides cell manufacturing and banking services. The company was formerly known as ThermoGenesis Corp. and changed its name to Cesca Therapeutics Inc. in February 2014. Cesca Therapeutics Inc. was founded in 1986 and is headquartered in Rancho Cordova, California. Cesca Therapeutics Inc. is a subsidiary of Boyalife (Hong Kong) Limited.Read More… Receive KOOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cesca Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KOOL Stock News HeadlinesNew book by Kool & the Gang member; Junior Police Academy a success | Journal EntriesAugust 11, 2023 | nj.comNSolo artist Cesca ‘happy’ to team up with BGYO’s MikkiJune 5, 2023 | msn.comWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave. | Crypto Swap Profits (Ad)'Maybe Next Time' adaptation: All we know about Apple Studios and Cesca Major movieMarch 25, 2023 | msn.comCesca Chairs Are Our Latest (But Oldest) Design ObsessionApril 29, 2022 | yahoo.comCesca’s ‘Pambihirang Harana’ song aims to normalize girls initiating relationshipsMarch 21, 2022 | msn.comSee More Headlines KOOL Stock Analysis - Frequently Asked Questions How were Cesca Therapeutics' earnings last quarter? Cesca Therapeutics Inc (NASDAQ:KOOL) released its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.27) EPS for the quarter. The biotechnology company earned $1.87 million during the quarter. Cesca Therapeutics had a negative net margin of 98.84% and a negative trailing twelve-month return on equity of 77.30%. Who are Cesca Therapeutics' major shareholders? Top institutional investors of Cesca Therapeutics include OLD Mission Capital LLC (1.40%) and Farther Finance Advisors LLC (0.22%). View institutional ownership trends. What other stocks do shareholders of Cesca Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cesca Therapeutics investors own include CTI BioPharma (CTIC), SCYNEXIS (SCYX), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), AbbVie (ABBV) and BioDelivery Sciences International (BDSI). Company Calendar Last Earnings5/14/2018Record date for 3/31 Dividend3/28/2025Ex-Dividend for 3/31 Dividend3/28/2025Dividend Payable3/31/2025Today6/27/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Laboratory Apparatus & Furniture Sub-IndustryN/A Current SymbolNASDAQ:KOOL CIK811212 Webwww.cescatherapeutics.com Phone916-858-5100FaxN/AEmployees53Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.72 million Net Margins-98.84% Pretax MarginN/A Return on Equity-77.30% Return on Assets-37.75% Debt Debt-to-Equity Ratio0.50 Current Ratio1.52 Quick Ratio0.91 Sales & Book Value Annual Sales$9.67 million Price / Sales2.92 Cash FlowN/A Price / Cash FlowN/A Book Value$3.11 per share Price / Book3.76Miscellaneous Outstanding Shares2,416,000Free FloatN/AMarket Cap$28.21 million OptionableNot Optionable Beta1.07 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:KOOL) was last updated on 6/28/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're currently collecting—or planning to collect—Social Security benefits, there's an urgent development ...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cesca Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cesca Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.